Core Insights - Guoyi Tong (Beijing) Technology Development Co., Ltd. has completed nearly 100 million yuan in Series D financing, led exclusively by Zhejiang Shengxie Health Fund [1] - The funds raised will primarily be used for the development of core research products, commercialization promotion, and the construction of new production lines [1] Company Overview - Since 2016, the company has focused on blood purification products and technology services, providing a comprehensive solution of "equipment + consumables + chronic disease management + medical services" for medical institutions and kidney disease patients [1] - The company's product business has covered over a thousand medical institutions, with a steadily increasing proportion of grassroots institutions, highlighting its leading advantage in the grassroots dialysis center market [1] Market Positioning - The company aligns well with the hierarchical diagnosis and treatment policy, effectively addressing the pain points of grassroots dialysis centers in terms of professional capability, operational efficiency, and talent shortages [1] Product Development - Guoyi Tong has established a closed-loop development model of "service empowering industrial innovation, industrial empowering service quality improvement," forming a rich product matrix including water treatment systems for hemodialysis, centralized liquid supply equipment, dialysis concentrates, and dialysis devices [1] - The company continues to promote technological breakthroughs and innovative research, developing key products such as peritonitis prediction systems (patented in the US, EU, and China), high and ultra-high permeability dialysis devices, peritoneal dialysis solutions, CRRT equipment, and related consumables [1] Strategic Growth - The company is also focusing on mergers and acquisitions in the blood purification industry to accelerate the comprehensive coverage of its blood purification product system, extending the entire chain and upgrading to intelligent solutions [1]

Core Viewpoint - Guoyi Tong (Beijing) Technology Development Co., Ltd. has completed nearly 100 million RMB in Series D financing, led exclusively by Zhejiang Shengxie Health Fund, to advance core products, market implementation, and new production line construction, marking a significant milestone for the company and the industry as it enters a "system construction cycle" [2] Industry Overview - The number of hemodialysis patients in China has exceeded one million and continues to grow, driven by aging population, rising diabetes rates, and early screening for chronic kidney disease (CKD), establishing a stable growth foundation for dialysis demand [3] - The hierarchical diagnosis and treatment policy is shifting the service focus from large hospitals to county and grassroots levels, leading to substantial changes in the geographical layout, supply structure, and business models of the dialysis system [3] Market Dynamics - Traditional large hospitals face significant pressure from long waiting times and commuting challenges, while grassroots dialysis centers are rapidly expanding due to policy encouragement and a mature industrial chain, creating new market opportunities [5] - Competition in the industry has evolved from focusing solely on equipment or consumables to encompassing comprehensive capabilities such as department construction, operational capacity, full-process services, and data security systems [5] Company Development - Founded in 2016, Guoyi Tong has focused on blood purification without pursuing rapid multi-category expansion, concentrating on dialysis department construction and supply system development [6] - The company has built a service model that includes "equipment + consumables + chronic disease management + services," serving over a thousand medical institutions, with an increasing proportion of grassroots institutions [6] Product Expansion - With the new financing, Guoyi Tong plans to expand its product and technology portfolio, including high-permeability dialyzers and peritoneal dialysis solutions, enhancing its adaptability in chronic disease management and critical care [7] - The company has developed a patented risk prediction system for peritonitis, reflecting its commitment to addressing clinical issues through digital solutions [7] Operational Capabilities - Guoyi Tong emphasizes dual development of industrial and service capabilities, establishing a systematic approach to dialysis center construction, equipment operation, and supply support [8] - This model addresses not only the sourcing of equipment but also the long-term stable operation of dialysis departments, which is crucial for patient quality of life [10] Future Outlook - The completion of the new production line will enhance the company's production flexibility, capacity assurance, and quality management, supporting the implementation of more scenarios [11] - The blood purification industry is transitioning from "shortcomings" to "system building," with the expansion of dialysis departments and the enhancement of county-level medical capabilities indicating long-term growth certainty [12]